GenVec Inc. Release: Long-Term Results From TNFerade(TM) Pancreatic Cancer Study And Updated Survival Results From TNFerade(TM) Esophageal Cancer Study Both Reported At Digestive Disease Week

GAITHERSBURG, Md.--(BUSINESS WIRE)--May 23, 2006--GenVec, Inc. (Nasdaq:GNVC - News) announced today that Kenneth Chang, M.D., medical director of the Comprehensive Digestive Disease Center at the University of California at Irvine and a clinical investigator for several studies involving GenVec's investigational cancer drug TNFerade(TM), presented updated survival information from a clinical study demonstrating the potential utility of TNFerade in treating patients with esophageal cancer. In an oral presentation yesterday at the annual Digestive Disease Week conference in Los Angeles, Dr. Chang reviewed evidence of esophageal tumor response to TNFerade when delivered by intratumoral injection once per week for five weeks with concurrent chemoradiation (cisplatin, 5-FU, radiation).